Authentica Global
Markets S&P 500 7,543.64 ▲ 0.81% Nasdaq 26,206.89 ▲ 1.30% Dow Jones 52,487.41 ▲ 0.27% US 10 Yr 4.54 ▼ 0.66% Crude Oil 71.87 ▼ 0.29% Gold 4,131.40 ▼ 0.23% Bitcoin 63,175 ▲ 1.51% FTSE 100 10,472.45 ▼ 0.16% EUR/USD 1.1436 ▲ 0.02% Nikkei 225 67,743.85 ▲ 1.38%
Topic archive

gedatolisib breast cancer FDA verdict

Reporting, analysis and commentary on gedatolisib breast cancer FDA verdict from Authentica Global, drawn together from across our coverage.

1 article Latest update: 5 Jul 2026 1 section
Related sections Health
Related topics gedatolisib Celcuity breast cancer PI3K inhibitors FDA approval VIKTORIA-1
Tag lead
FDA headquarters signage representing the pending regulatory decision on gedatolisib for advanced breast cancer
Health

Gedatolisib Breast Cancer FDA Verdict Nears for Patients Out of Options

Gedatolisib, Celcuity's PI3K/mTOR inhibitor, faces a July 17, 2026 FDA decision that could deliver the first targeted therapy for HR-positive, PIK3CA wild-type advanced breast cancer patients with no options after CDK4/6 and hormone therapy.

5 Jul 2026 ·8 min read
Keep reading

More paths through this story

This archive gathers Authentica Global coverage of gedatolisib breast cancer FDA verdict, bringing together the reporting, analysis and commentary connected to the subject.

Related topics

gedatolisib Celcuity breast cancer PI3K inhibitors FDA approval VIKTORIA-1 Federal Reserve Donald Trump AI infrastructure nonfarm payrolls

Related sections

Health

Latest nearby

Health · 5 Jul 2026 Colorado Enbrel Price Cap Blocked, Pharma Pockets the Win Health · 5 Jul 2026 US Measles Elimination Status 2026 Cracks at 2,170 Cases Health · 5 Jul 2026 Aetna, Cigna Headline ACA Marketplace Insurers Exit 2026 Health · 5 Jul 2026 Dead Skua Marks First H5N1 Bird Flu Australia Detection